In 2003, the United States launched the President's Emergency Plan for AIDS Relief, the largest commitment by any nation to fight a single disease. That same year, diarrheal disease killed well over a million people, most of them children under five, and no comparable initiative followed. Two decades later, PEPFAR has invested more than $110 billion. Diarrhea, still among the leading killers of young children worldwide, has never had an emergency plan of its own.

This is not an accident of epidemiology. The burden of a disease and the attention it receives are only loosely related. Political scientists who study global health priority-setting, notably Jeremy Shiffman, have shown that a condition's rise on the agenda depends less on how many people it kills than on three things: who those people are, how the problem is framed, and whether anyone is organised enough to force the issue onto the desks of ministers and donors.

Understanding this political economy of attention matters for anyone working in international health. It explains why funding flows look the way they do, why many health systems are built around a handful of vertical programmes, and why whole categories of suffering stay invisible. It also offers a practical lesson. Attention is manufactured, not given. The mechanics of that manufacture can be studied, learned, and sometimes redirected toward the conditions that need it most.

Who Suffers Determines Who Speaks

The early HIV epidemic in North America and Western Europe struck a population with distinctive characteristics. Gay men in cities like New York and San Francisco were often educated, socially networked, and already politically organised through the gay liberation movement of the 1970s. They had media contacts, legal expertise and, critically, the capacity to speak for themselves. The epidemic arrived in a community that already knew how to fight.

Contrast this with diarrheal disease. Its victims are overwhelmingly young children in low-income settings across sub-Saharan Africa and South Asia. Their parents are frequently poor, rural, and far removed from national policy processes, let alone the meeting rooms of Geneva and Washington. A two-year-old in rural Bihar cannot form an advocacy coalition. In practice, neither can her mother, who may be managing the same risk for several children at once.

Celebrity involvement amplifies these dynamics. Rock Hudson's death in 1985, Elizabeth Taylor's founding role in amfAR, Princess Diana's ungloved handshake with an AIDS patient in 1987, and Magic Johnson's 1991 announcement each shifted public perception. Celebrities offer more than visibility. They create a sense of proximity: if it can happen to them, it can happen to anyone. Diseases of poverty rarely offer that bridge, because they rarely touch the famous.

Proximity to power matters even more than fame. Breast cancer built formidable advocacy infrastructure in wealthy countries partly because it affects women across income levels, including legislators, journalists, and philanthropists. Tuberculosis, which the WHO again ranks as the world's leading infectious killer, sits at the other end. It concentrates among prisoners, miners, migrants, and the urban poor, groups with limited political leverage almost everywhere. Its death toll has long exceeded HIV's, yet its activist base remains comparatively thin.

The organisation of affected populations is often decisive. Diseases that strike people capable of collective action tend to generate movements. Diseases that strike the voiceless depend on proxies such as NGOs, academics, and foundations to speak for them. Proxies can be effective and technically sophisticated, but they rarely produce the moral force that comes from affected people themselves demanding the right to survive.

Takeaway

Disease burden does not become political priority on its own; it passes through the filter of who is affected and whether they can organise. The most neglected conditions are often those whose victims have the least voice.

The Stories That Make Suffering Legible

Movements do not simply amplify suffering; they interpret it. Successful health campaigns tend to frame their cause in one of three ways: as an emergency demanding immediate action, as an injustice requiring redress, or as a solvable problem awaiting investment. The most powerful movements manage all three at once, and each frame reinforces the others.

HIV activism achieved exactly this combination. ACT UP, founded in 1987, framed the epidemic as an emergency through its stark slogan 'Silence = Death.' South Africa's Treatment Action Campaign, formed in 1998, recast antiretroviral access as a human rights struggle that set dying patients against pharmaceutical patents. Once combination therapy arrived in 1996, solvability became undeniable: people were dying of a treatable disease simply because they were poor.

Diarrheal disease resists each of these frames. It is endemic rather than epidemic, a constant background toll rather than a sudden crisis. Outside cholera outbreaks, such as the one that devastated Haiti after 2010, it rarely produces the spike in deaths that news systems recognise. Its injustice is real but diffuse, spread across poverty, sanitation, nutrition, and governance, with no obvious villain. There is no patent holder to confront and no government that refused a cure.

Its cheapness may even work against it. Oral rehydration solution, which The Lancet in 1978 called potentially the most important medical advance of the century, costs very little and carries no intellectual property. Without a profitable product, no industry champion emerges. The deeper solutions, clean water and sanitation, are split across ministries of health, water, and infrastructure, so responsibility dissolves into the gaps between bureaucracies.

Some advocates have learned to construct narratives where none existed. In the mid-2000s, a set of disparate parasitic and bacterial infections was grouped under the label 'neglected tropical diseases.' The brand gave them a collective identity and a fundable story: donated drugs, mass administration, low cost per person treated. The 2012 London Declaration on NTDs followed. Naming the neglect became the first step toward reducing it.

Takeaway

A disease's narrative potential is partly inherent and partly constructed. Where there is no obvious emergency, villain, or cure, advocates can sometimes create a story by grouping, renaming, and reframing what already exists.

What Advocacy Actually Delivered

Measured against its own goals, HIV advocacy stands among the most consequential social movements of the past half-century. Funding expanded dramatically in the 2000s through the Global Fund, established in 2002, and PEPFAR, launched a year later. For years HIV commanded a large share of all donor assistance for health. PEPFAR alone is credited with saving more than 25 million lives.

The policy victories were just as significant. Activist pressure helped speed up drug approval pathways in the United States. The 2001 Doha Declaration affirmed that patent rules should not prevent countries from protecting public health. Generic competition, driven largely by Indian manufacturers, pushed the annual cost of first-line antiretrovirals from more than $10,000 per patient to under $100. Jim Yong Kim's '3 by 5' initiative at the WHO helped show that mass treatment in low-income settings was feasible.

Yet the success of disease-specific advocacy raises uncomfortable questions. Laurie Garrett and others have argued that vertical funding streams distorted fragile health systems, drawing scarce health workers into well-paid HIV programmes while primary care struggled. Disease silos can produce parallel supply chains, duplicate reporting systems, and clinics that manage one condition expertly but cannot treat a feverish child with pneumonia.

Meanwhile, quieter progress tells its own story. Diarrheal deaths among children have fallen substantially since 1990, driven by oral rehydration, zinc supplementation, rotavirus vaccines delivered with Gavi support, and gradual improvements in water and sanitation. This happened without a mass movement, propelled instead by technical networks, multilateral agencies, and economic growth. Polio eradication, sustained for decades by Rotary International's volunteer networks, offers a third model: persistent institutional advocacy rather than street protest.

What set the most effective movements apart was the pairing of moral urgency with concrete, fundable demands. ACT UP did more than protest; it produced detailed treatment agendas with specific scientific requests. The Treatment Action Campaign went to court and, in 2002, won a Constitutional Court ruling requiring the South African government to expand access to drugs that prevent mother-to-child transmission. Grievance plus a credible plan turns attention into lasting resources. Awareness without a clear demand tends to fade.

Takeaway

Advocacy works best when outrage is tied to a specific, achievable demand. Because one disease's victory can strain the systems that serve every disease, the real question is not only how to win attention but how to share it.

The gap between HIV and diarrheal disease is not a story of one group caring more than another. It reflects structural features: who gets sick, whether they can organise, whether their suffering fits a compelling story, and whether there is a clear solution to demand.

International experience suggests these features are not fixed. Neglected tropical diseases gained a name and a constituency. Polio gained a tireless institutional champion. Child deaths from diarrhea declined through technical networks working largely out of the spotlight. Attention can be built, borrowed, and redistributed.

The deeper lesson may be that global health needs advocacy for systems as much as for diseases. Universal health coverage, primary care, and clean water lack the emotional pull of a single named killer, yet they protect against all of them. The next great health movement may be the one that makes the unglamorous feel urgent.